225 related articles for article (PubMed ID: 16153448)
1. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Rundall BK; Denlinger CE; Jones DR
Surgery; 2005 Aug; 138(2):360-7. PubMed ID: 16153448
[TBL] [Abstract][Full Text] [Related]
2. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
Rundall BK; Denlinger CE; Jones DR
Surgery; 2004 Aug; 136(2):416-25. PubMed ID: 15300209
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Denlinger CE; Rundall BK; Jones DR
J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
[TBL] [Abstract][Full Text] [Related]
5. The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.
Kim MK; Jeon YK; Woo JK; Choi Y; Choi DH; Kim YH; Kim CW
Mol Cancer; 2011 Aug; 10():98. PubMed ID: 21843371
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo.
Zheng L; Fu Y; Zhuang L; Gai R; Ma J; Lou J; Zhu H; He Q; Yang B
Int J Cancer; 2014 Oct; 135(7):1721-32. PubMed ID: 24615207
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Imre G; Gekeler V; Leja A; Beckers T; Boehm M
Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
Arnold NB; Arkus N; Gunn J; Korc M
Clin Cancer Res; 2007 Jan; 13(1):18-26. PubMed ID: 17200334
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis.
Jones DR; Broad RM; Madrid LV; Baldwin AS; Mayo MW
Ann Thorac Surg; 2000 Sep; 70(3):930-6; discussion 936-7. PubMed ID: 11016336
[TBL] [Abstract][Full Text] [Related]
11. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
12. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.
Takada Y; Gillenwater A; Ichikawa H; Aggarwal BB
J Biol Chem; 2006 Mar; 281(9):5612-22. PubMed ID: 16377638
[TBL] [Abstract][Full Text] [Related]
13. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Jeon HG; Yoon CY; Yu JH; Park MJ; Lee JE; Jeong SJ; Hong SK; Byun SS; Lee SE
J Urol; 2011 Nov; 186(5):2084-93. PubMed ID: 21944112
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Hanke NT; Garland LL; Baker AF
J Cancer Res Clin Oncol; 2016 Mar; 142(3):549-60. PubMed ID: 26385374
[TBL] [Abstract][Full Text] [Related]
15. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
[TBL] [Abstract][Full Text] [Related]
16. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Denlinger CE; Keller MD; Mayo MW; Broad RM; Jones DR
J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1078-86. PubMed ID: 15052205
[TBL] [Abstract][Full Text] [Related]
17. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Lee JK; Ryu JK; Yang KY; Woo SM; Park JK; Yoon WJ; Lee SH; Jeong KS; Kim YT; Yoon YB
Pancreas; 2011 Aug; 40(6):966-73. PubMed ID: 21487323
[TBL] [Abstract][Full Text] [Related]
18. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
[TBL] [Abstract][Full Text] [Related]
19. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of nuclear factor kappaB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation.
Jones DR; Broad RM; Comeau LD; Parsons SJ; Mayo MW
J Thorac Cardiovasc Surg; 2002 Feb; 123(2):310-7. PubMed ID: 11828291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
